Nicholas R Casewell
Biographic Data
| ID | 9075830 |
|---|---|
| NAME | Nicholas R Casewell |
| GIVEN NAMES | Nicholas R |
| FAMILY NAME | Casewell |
| SIGNATURE | CASEWELL N R |
| AFFILIATIONS | Liverpool School of Tropical Medicine |
| ORCID | 0000-0002-8035-4719 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
From scarcity to sustainability
Snakebite envenoming (SBE) causes substantial mortality and long-term disability in sub-Saharan Africa (SSA), disproportionately affecting rural and economically vulnerable populations. Antivenom is currently the only approved snakebite therapy, yet chronic shortages, fragmented supply chains, high prices, and inconsistent product quality continue to undermine access, exacerbated further by persistent gaps in human resource capacity and health sy…
African polyvalent antivenom can maintain pharmacological stability and ability to neutralise murine venom lethality for decades post-expiry
INTRODUCTION: Antivenom is a lifesaving medicine for treating snakebite envenoming, yet there has been a crisis in antivenom supply for many decades. Despite this, substantial quantities of antivenom stocks expire before use. This study has investigated whether expired antivenoms retain preclinical quality and efficacy, with the rationale that they could be used in emergency situations when in-date antivenom is unavailable. METHODS: Using WHO gui…
No prominent works on this page.
African polyvalent antivenom can maintain pharmacological stability and ability to neutralise murine venom lethality for decades post-expiry
INTRODUCTION: Antivenom is a lifesaving medicine for treating snakebite envenoming, yet there has been a crisis in antivenom supply for many decades. Despite this, substantial quantities of antivenom stocks expire before use. This study has investigated whether expired antivenoms retain preclinical quality and efficacy, with the rationale that they could be used in emergency situations when in-date antivenom is unavailable. METHODS: Using WHO gui…
From scarcity to sustainability
Snakebite envenoming (SBE) causes substantial mortality and long-term disability in sub-Saharan Africa (SSA), disproportionately affecting rural and economically vulnerable populations. Antivenom is currently the only approved snakebite therapy, yet chronic shortages, fragmented supply chains, high prices, and inconsistent product quality continue to undermine access, exacerbated further by persistent gaps in human resource capacity and health sy…
Antivenom (2 works) · Healthcare and Venom Research (2 works) · Venomous Animal Envenomation and Studies (2 works) · Biology (1 work) · Capacity building (1 work) · Economic shortage (1 work) · Health Policy (1 work) · Health Policy (1 work) · Healthcare system (1 work) · Intensive care medicine (1 work)